Physician profile
Daniel R Halili
NPI 1366411480
$6,846.49
in general payments reported to CMS, 2019-2025
54 companies · $67.92 in 2025
The $67.92 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,422 · 2020: $211 · 2021: $1,080 · 2022: $1,416 · 2023: $1,135 · 2024: $1,515 · 2025: $67.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,718.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $689.68 | 2019-2024 | |
| Astellas Pharma US INC | $423.49 | 2019-2023 | Padcev |
| Pfizer INC. | $420.82 | 2019-2024 | |
| Lilly USA, LLC | $418.61 | 2019-2024 | Verzenio, Retevmo, Jaypirca |
| Merck Sharp & Dohme LLC | $377.89 | 2019-2024 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $367.95 | 2019-2024 | Lynparza, Enhertu, Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $286.73 | 2019-2024 | |
| Seagen INC. | $280.04 | 2019-2023 | Tukysa, Adcetris |
| Incyte Corporation | $276.44 | 2020-2025 | Jakafi, Monjuvi |
| Janssen Biotech, INC. | $273.70 | 2019-2024 | Imbruvica, Darzalex, Erleada |
| Novocure INC. | $234.00 | 2019-2021 | |
| Brainlab, INC. | $221.58 | 2019 | |
| Celgene Corporation | $215.17 | 2019-2024 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $166.04 | 2019-2024 | Ninlaro, Iclusig |
| Daiichi Sankyo INC. | $165.04 | 2021-2024 | Enhertu |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Halili listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.